HAPPE Spine, an early-stage company advancing clinical outcomes with a proprietary biomaterial and manufacturing platform for creating bone-integrating implants, announces that the INTEGRATE®-C Interbody Fusion System has been implanted in more than 1,000 patients, demonstrating clinical adoption of the HAPPE® platform across more than 30 surgeon users and 40 facilities nationwide.
Dr. George S. Naseef, MD, President of the Advanced Spine Center and Interim-Chairman of the Department of Orthopedic Surgery at Morristown Medical Center in New Jersey said, “I have been extremely satisfied with the HAPPE INTEGRATE®-C. In my patients, I am seeing earlier fusion and higher fusion rates compared to 3D-printed metal devices, especially in multilevel cases. Post-operative imaging is not inhibited by metal artifact and the interference fit of the INTEGRATE®-C in the disc space feels more stable compared to PEEK devices I have used.”
HAPPE Spine closed an oversubscribed bridge funding round earlier this year to support continued clinical validation of the HAPPE platform in the INTEGRATE®-C Interbody Fusion System, and expansion of manufacturing capabilities to support commercial growth and future product offerings.
HAPPE Spine also announces completion of the MedTech Innovator 2025 Accelerator Cohort. HAPPE was one of only 65 companies—representing the top 4% of nearly 1,500 global applicants—chosen to participate in this year’s program. MedTech Innovator is the world’s largest accelerator for medical technology startups boasting over 700 alumni companies that have collectively raised more than $10B in follow-on funding and introduced more than 500 products to market.
